Denyes Nancy bought $9,276 worth of shares (5,000 units at $1.86), increasing direct ownership by 29% to 22,267 units (SEC Form 4)

$LIFE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $LIFE alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DENYES NANCY

(Last) (First) (Middle)
10240 SORRENTO VALLEY ROAD
SUITE 300

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
aTYR PHARMA INC [ ATYR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/05/2024 P 5,000 A $1.8552(1) 22,267(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.835 to $1.87 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
2. Includes 2,500 shares acquired on May 15, 2024 under the Company's 2015 Employee Purchase Plan.
/s/ Nancy E. Denyes 06/06/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $LIFE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LIFE

DatePrice TargetRatingAnalyst
7/5/2023Outperform → Perform
Oppenheimer
11/11/2021$18.00 → $11.00Buy
HC Wainwright & Co.
11/11/2021$18.00 → $11.00Action List Buy
HC Wainwright & Co.
10/12/2021$22.00Outperform
RBC Capital
9/21/2021$19.00Overweight
Piper Sandler
9/14/2021$20.00 → $21.00Buy
Roth Capital
9/14/2021$14.00 → $20.00Outperform
Oppenheimer
9/13/2021$13.00 → $18.00Buy
HC Wainwright & Co.
More analyst ratings

$LIFE
Press Releases

Fastest customizable press release news feed in the world

See more
  • aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from "LIFE" to "ATYR"

    SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will be changing its ticker symbol from "LIFE" to "ATYR." Effective at the market open on June 5, 2024, the Company's common stock will trade on the Nasdaq Capital Market under the new symbol "ATYR." "As we advance our lead therapeutic candidate, efzofitimod, through a pivotal Phase 3 study in pulmonary sarcoidosis and prepare for potential commercialization, the "ATYR" ticker symbol is a strong reflec

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, May 24, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 9,400 shares of aTyr's common stock, each with an exercise price of $1.86 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on May 22, 2024, the effective date of the grants. These stock awards were granted as an inducement material

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

    SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2024 International Conference, which is scheduled to take place May 17 – 22 in San Diego, CA. "These findings further demonstrate the unique way in which efzofitimod is modulating myeloid cells to confer the anti-inflammatory benefits we have seen in patients with pulmonary sarcoidosis, a major form o

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$LIFE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$LIFE
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$LIFE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$LIFE
SEC Filings

See more

$LIFE
Leadership Updates

Live Leadership Updates

See more
  • aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

    SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023. "We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Dr. Frederick's clinical background combined with

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

    SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Danielle Campbell to Vice President, Human Resources. Ms. Campbell will serve as a member of the company's executive leadership team and oversee all aspects of human resources strategies and functions, including organizational development, talent management and talent acquisition initiatives. "We are delighted to welcome Danielle to aTyr at a pivotal time in the company's journey as we expand our team to support our next phase of growth," said Sanjay S.

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

    NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ

    $AMGN
    $APVO
    $BCTX
    $BMY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

$LIFE
Financials

Live finance-specific insights

See more
  • aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

    Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

    SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 14, 2024Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b7

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results

    SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate update after the market close on Thursday, March 9, 2023. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 9, 2023Time: 5:00 p.m. EST / 2:00 p.m. PSTDial-In Registration: https://register.vevent.com/register/BI01f8362bebee42539116051

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$LIFE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more